CervoMed (CRVO) is climbing 3% after Boral Capital upgraded the shares to Buy from Hold. The investment bank placed a $10 price target on the drug maker. Why Boral Upgraded CRVO After meeting with ...

[46] The study also showed that CRVO treatment with an anti-VEGF agent used on a monthly basis for 6 months followed by PRN produces significantly better results in all end points compared with sham.

Recently, an alternative longer acting steroid, dexamethasone implant (Ozurdex), had been extensively studied and gained licensing for its efficacy in treating CRVO-ME. The Ozurdex trial compared ...

Fintel reports that on February 19, 2025, D. Boral Capital upgraded their outlook for CervoMed (NasdaqCM:CRVO) from Hold to Buy. As of February 18, 2025, the average one-year price target for ...